| Autor: |
Nimer S. Alkhatib, Abdulaali R. Almutairi, Omar S. Alkhezi, Osama M. Alfayez, Majed S. Al Yami, Omar A. Almohammed |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Saudi Pharmaceutical Journal, Vol 30, Iss 4, Pp 433-439 (2022) |
| Druh dokumentu: |
article |
| ISSN: |
1319-0164 |
| DOI: |
10.1016/j.jsps.2022.01.018 |
| Popis: |
Objectives: To perform a cost of control analysis of glucagon like peptide-1 receptor agonists (GLP1RA) in Saudi Arabia (SA) and determine the economic impact of adopting GLP1RAs. Methods: A budget impact model that captures the cost of control model was constructed to simulate hypothetical patient on six treatment options: a current mix of 60% liraglutide and 40% dulaglutide, semaglutide, liraglutide, dulaglutide, exenatide, and lixisenatide. We estimated the relative amounts of SAR spend to achieve HbA1c targets (≤6.5% or |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
